NAICS 325412: Pharmaceutical Preparation Manufacturing
This U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

ExioML sector: Chemicals nec
Region: US | Year: 2022
Sector value added: 183879.917188 M EUR | Employment: 2033.54236812 thousand persons
Sector GHG emissions: 125728834468.0 kg CO2 eq | Energy carrier net total: 3186425.50957 TJ | Carbon intensity: 0.6837551179635024

Company: Human Genome Sciences Inc
Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company products predict, prevent, detect, treat, and cure disease based on the discovery of human, and microbial genes.